Clinical trials: Severe Psoriasis
Psoriasis
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
efficacy study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206387
- Testing
- Desoximetasone Spray 0.25%
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate to Severe Plaque Psoriasis
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to develop a database containing patient-reported information that may be used to understand and to increase awareness of the impact that moderate-to-severe plaque psoriasis can have on both daily life…
- Trial name
- NCT01555606
- Testing
- No intervention
- Where
- 9 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Biotech, Inc.
Chronic Plaque Psoriasis
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs.
- Trial name
- BELIEVE (NCT00574249)
- Testing
- adalimumab, Calcipotriol/Betamethasone Ointment
- Where
- 131 sites in Austria, Belgium and 13 more
- Volunteers
- 730 people
- Sponsor
- Abbott
Psoriasis
Therapeutic Education Program in Psoriasis
The primary objective of this research protocol is to assess the effect of a structured therapeutic education program on the quality of life of patients with moderate to severe psoriasis
- Trial name
- EDUPSO (NCT02310204)
- Testing
- multidisciplinary education program, standard psoriasis care alone
- Where
- 9 sites in France
- Volunteers
- 187 people
- Sponsor
- University Hospital, Toulouse
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01230138
- Testing
- FP187
- Where
- 2 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Forward-Pharma GmbH
Moderate-to-Severe Plaque Psoriasis
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.
- Trial name
- NCT06182384
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis Vulgaris
The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.
This is a 12-week treatment, singlecenter, open-label, single-arm, dose-selection, proof of concept study to determine a dosage of HSP 90 inhibitor (CUDC-305) that is tolerable and demonstrates preliminary efficacy for use in…
- Trial name
- NCT03675542
- Testing
- CUDC-305
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Aarhus University Hospital
Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy
The efficacy of TNF alfa inhibitors in the treatment of psoriasis has been documented in many studies. Their effect on dendritic cells has been scarcely studied.
- Trial name
- ELIDACE (NCT01237262)
- Testing
- Adalimumab, etanercept, infliximab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Padova
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT01970488
- Testing
- Adalimumab, ABP 501
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Plaque Psoriasis, Healthy Volunteer
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.
- Trial name
- NCT07038720
- Testing
- UA026
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Usynova Pharmaceuticals Ltd.
Psoriasis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other…
- Trial name
- NCT01837420
- Testing
- VB-201 80mg, VB-201 160mg
- Where
- 4 sites in Germany, Israel and 2 more
- Volunteers
- 194 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Psoriasis
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03210259
- Testing
- Humira®, BI 695501
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis, Moderate to Severe
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
- Trial name
- NCT00162253
- Testing
- BMS 587101
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective observational study. The main purpose of this study is to assess the effect of tildrakizumab on the overall wellbeing in patients with…
- Trial name
- POSITIVE (NCT04823247)
- Testing
- Tildrakizumab
- Where
- Germany
- Volunteers
- 782 people
- Sponsor
- Almirall, S.A.
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Plaque Psoriasis
Safety and Efficacy Study of CF101 to Treat Psoriasis
This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis.
- Trial name
- NCT00428974
- Testing
- CF101 1mg, CF101 2mg, CF101 4mg
- Where
- 4 sites in Israel
- Volunteers
- 76 people
- Sponsor
- Can-Fite BioPharma